The Latest Breaking News from CI

Despite Cigna Group’s recent underperformance relative to the Dow, Wall Street analysts remain strongly optimistic about the stock’s prospects.

The healthcare industry thrives due to novel drug pipeline discoveries, AI integration to streamline processes and technological advancements. So, investing in undervalued healthcare stocks with upside potential, Pfizer (PFE), Cigna Group (CI), and Centene Corp (CNC), could be a wise idea. Keep reading….

Investing in growth stocks is appealing due to attractive pricing, stable business activity, easing inflation, and the Fed's gradual rate cuts, all of which create a favorable environment for capital gains. With a positive global economic outlook, it could be wise to consider investing in stocks that Wall Street loves…

With rising medical costs and an expanding aging population, the health insurance sector is set to witness significant growth. Hence, investors looking to capitalize on this trend could consider stable health insurance stocks Elevance Health (ELV), Cigna Group (CI), and Centene (CNC). Read on….

The healthcare sector is set for robust growth, driven by surging demand for quality treatments, a growing patient base, breakthroughs in biopharma, and supportive policies. Therefore, investors could consider undervalued pharmaceutical stocks like Merck & Co. (MRK), Pfizer (PFE), and Cigna (CI) with significant upside potential. Read more.

The Cigna Group has outperformed the Nasdaq Composite over the past year and analysts remain bullish about the stock’s prospects.

Blue-chip stocks offer stability and consistent growth irrespective of market conditions. Thus, blue chip names Lockheed Martin (LMT), Regeneron Pharmaceuticals (REGN), and Cigna Group (CI) could be prudent additions to your portfolios. These stocks are Strong Buy-rated in our proprietary POWR Ratings system. Read on.

Cigna Group has underperformed the broader market over the past year, but Wall Street analysts are optimistic about the stock’s prospects.

Here’s a dividend-paying gem trading at an attractive valuation, which investors can consider this July while it's still a bargain.